Alnylam Pharmaceuticals
Clinical trials sponsored by Alnylam Pharmaceuticals, explained in plain language.
-
New injection for rare protein disease passes first safety check
Disease control CompletedThis early-stage study tested a new drug called ALN-TTRSC04 in 96 healthy people to see if it is safe and how the body processes it. The drug aims to lower a harmful protein that causes transthyretin amyloidosis, a serious disease affecting nerves and the heart. Participants rece…
Phase: PHASE1 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:16 UTC
-
New shot could tame high blood pressure without daily pills
Disease control CompletedThis study tested an experimental drug called ALN-AGT01 in 394 adults with mild-to-moderate high blood pressure. The goal was to see if it safely lowers blood pressure over three months compared to a placebo. Participants did not take other blood pressure medicines during the stu…
Phase: PHASE2 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:16 UTC
-
New blood pressure drug shows promise in japanese study
Disease control CompletedThis study tested a new medicine called zilebesiran in 36 Japanese adults with mild to moderate high blood pressure. The goal was to see if it is safe and helps lower blood pressure over 6 months. Participants received either the drug or a placebo, and researchers measured blood …
Phase: PHASE1, PHASE2 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
New drug shows promise for rare heart disease in major trial
Disease control CompletedThis study tested a drug called patisiran in 360 people with a rare condition where abnormal protein builds up in the heart, causing heart failure. The goal was to see if patisiran could improve how far patients can walk in 6 minutes and their heart-related quality of life after …
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New shot helps lower stubborn blood pressure in high-risk patients
Disease control CompletedThis study tested an experimental drug called zilebesiran in 375 adults with high cardiovascular risk and high blood pressure that wasn't well controlled by their current medications. Participants received zilebesiran or a placebo added to their usual pills. The main goal was to …
Phase: PHASE2 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
New hope for stubborn high blood pressure: experimental drug shows promise in large trial
Disease control CompletedThis study tested an experimental drug called zilebesiran in 663 adults whose high blood pressure was not well controlled by standard medications. Participants took zilebesiran or a placebo alongside their usual blood pressure pills. The goal was to see if adding zilebesiran coul…
Phase: PHASE2 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
New shot every 3 months shows promise for rare nerve disease
Disease control CompletedThis study tested a new drug called vutrisiran in 164 adults with a rare inherited disease that damages nerves and organs. Participants received either vutrisiran every 3 months or a standard treatment every 3 weeks. The goal was to see if vutrisiran could slow nerve damage and i…
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 18, 2026 12:02 UTC
-
New drug ALN-AGT01 RVR tested in healthy people for safety
Knowledge-focused CompletedThis early-stage study tested the safety and how the body processes a single dose of ALN-AGT01 RVR in 42 healthy adults. Participants received either the drug or a placebo, and researchers monitored for side effects and drug levels in blood and urine. The goal was to gather initi…
Phase: PHASE1 • Sponsor: Alnylam Pharmaceuticals • Aim: Knowledge-focused
Last updated May 26, 2026 02:48 UTC